Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Despite Few Actions On Rx Drug Promos, US FDA Increased Engagement With Stakeholders Last Year

Executive Summary

Office of Prescription Drug Promotion issued six enforcement letters and launched three research projects in 2021. There were more internal changes as the office switched to electronic submissions of promotional materials and went through year-end reorganization.

You may also be interested in...



What Trade-Offs Do Consumers And Physicians Make In Choosing Rx Drug Treatments?

US FDA study is to examine the relative importance of product information, such as efficacy, risk and patient preference claims, in the treatment preferences of consumers and physicians.

Rx Drug Promotion: Inclusion Of Extensive Risk Info In Twitter, Google Ads Has Potential Drawback

US FDA study of character-space-limited prescription drug communications finds consumers may be less likely to click on a link for more risk information if the promo already has substantial details.

Lilly Gets First Of Its Kind FDA Citation For Trulicity Instagram Post

Promotion does not adequately communicate the diabetes drug’s indication, limits of use and risks, FDA says. It objects to distracting visuals in video and less prominent risk information. Agency had previously relayed its concerns to Lilly about Trulicity promotions.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel